Effect Evaluation Of Combination Therapy With Amlodipine Plus Terazosin In Patients With Concurrent Benign Prostatic Hyperplasia And Hypertension

Objectives: To evaluate efficacy of combination therapy with amlodipine and terazosin in middle aged and old male patients with concurrent benign prostatic hyperplasia and hypertension, to evaluate the QOL of the patients with Concurrent Benign Prostatic Hyperplasia and Hypertension,to compare the QOL and clinical indexes between pre and post treatment.Methods: Randomized, double-blinded, parallel study was carried out in the patients with concurrent benign prostatic hyperplasia and hypertension in Anqing community between August 2007 and Dcember 2007. After informed consent , all patients were randomly divided into three groups and given amlodipine 5mg,terazosin 1mg, amlodipine 5mg plus terazosin 1mg. once /per day before sleep ,for 4 weeks.Who take Terazosin need change the dose to 2mg from 5th day.SF-36,IPSS and the basic status questionnaire were used to make surveys on the patients. In this article, we chose 360 patients who completed the study to analysis the efficacy of the different therapies and the QOL.Result: 1. After statistical analysis, amlodipine group, terazosin group and the combine group had no different in clinical and demographic characteristics,except in the weight.2. The SF-36 subsacales of Concurrent Benign Prostatic Hyperplasia and Hypertension were significantly lower than normal population.3. Comparison for SF-36 subscales of patients between pre and post treatment in different groups:(1)The seven SF-36 subacales of amlodipine group in post treatment were higher than pre treatment,except BP have no different(P<0.01).(2)The QOL of terazosin group had no different between pre and post treatment in PF,BP and SF in post treatment were higher than pre treatment(P<0.05).(3)PF of combine group in post treatment was higher than pre treatment and other seven subscales were singnificantly higher than pre treatment (P<0.01).4. Comparison for IPSS of patients between pre and post treatment in different groups:(1) The IPSS of amlodipine group, terazosin group and the combine group in post treatment were lower than pre treatment.5.Comparison of clinical indexes of patients between pre and post treatment in different groups: (1)The DBP,SBP, prostatic volume of amlodipine group in post treatment were significantly lower than pre treatment(P<0.01),but the residual urine volume,maximum urinary rate,average urinary flow rate had no different.(2) The DBP,SBP, prostatic volume and residual urine volume of terazosin group in post treatment were significantly lower than pre treatment(P<0.01), but the maximum urinary rate,average urinary flow rate had no different.(3) )The DBP,SBP, prostatic volume and residual urine volume of combine group in post treatment were significantly lower than pre treatment(P<0.01),the maximum urinary rate,average urinary flow rate had no different.(4) P value of the difference of residual urine volume between pre and psot treatment in amlodipine group equal to 0.054, P value of terazosin group and combine group equal to 0.001,the latter′significance was higher than the former.6. Comparison of improved range of QOL,IPSS,and clinical indexes between pre and post treatment in three groups:(1)The improved range of SF-36 subscales in different groups have no different.(2)The improved range of IPSS in different groups have no different.(3)The improved range of DBP,SBP, prostatic volume, residual urine volume,maximum urinary rate,average urinary flow rate had no different.Conclusions:The QOL of concurrent benign prostatic hyperplasia and hypertension was significantly lower than normal population.After treatment,the SF-36 subsacles of patients increased,blood preassure and IPSS significantly decreased, rostatic volume, residual urine volume,maximum urinary rate,and average urinary flow rate had been improved,using terazosin and drug combination were better than using amlodipine in improving the residual urine volume,drug combination was better than using single drug.The improved change of SF-36 subascales IPSS, DBP,SBP, prostatic volume, residual urine volume,maximum urinary rate,average urinary flow rate had no different in three groups.